Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. Background:Predictive performance of polygenic risk scores (PRS) varies across populations. To facilitate equitable clinical use, we developed PRS for coronary heart disease (CHD; PRSCHD) for 5 genetic ancestry groups.Methods:We derived ancestry-specific and multi-ancestry PRSCHDbased on pruning and thresholding and continuous shrinkage priors (polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods) applied to summary statistics from the largest multi-ancestry genome-wide association study meta-analysis for CHD to date, including 1.1 million participants from 5 major genetic ancestry groups. Following training and optimization in the Million Veteran Program, we evaluated the best-performing PRSCHDin 176 988 individuals across 9 diverse cohorts.Results:Multi-ancestry polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods outperformed ancestry-specific Polygenic risk score for CHD developed using pruning and thresholding methods and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods across a range of tuning values. Two best-performing multi-ancestry PRSCHD(ie, polygenic risk score for CHD developed using pruning and thresholding methods optimized using a multi-ancestry population and polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population) and 1 ancestry-specific (PRSCSxEUR) were taken forward for validation. Polygenic risk score for CHD developed using pruning and thresholding methods (PT) optimized using a multi-ancestry population demonstrated the strongest association with CHD in individuals of South Asian genetic ancestry and European genetic ancestry (odds ratio per 1 SD [95% CI, 2.75 [2.41–3.14], 1.65 [1.59–1.72]), followed by East Asian genetic ancestry (1.56 [1.50–1.61]), Hispanic/Latino genetic ancestry (1.38 [1.24–1.54]), and African genetic ancestry (1.16 [1.11–1.21]). Polygenic risk score for CHD developed using ancestry-based continuous shrinkage methods optimized using a multi-ancestry population showed the strongest associations in South Asian genetic ancestry (2.67 [2.38–3.00]) and European genetic ancestry (1.65 [1.59–1.71]), lower in East Asian genetic ancestry (1.59 [1.54–1.64]), Hispanic/Latino genetic ancestry (1.51 [1.35–1.69]), and the lowest in African genetic ancestry (1.20 [1.15–1.26]).Conclusions:The use of summary statistics from a large multi-ancestry genome-wide meta-analysis improved the performance of PRSCHDin most ancestry groups compared with single-ancestry methods. Despite the use of one of the largest and most diverse sets of training and validation cohorts to date, improvement of predictive performance was limited in African genetic ancestry. This highlights the need for larger Genome-wide association study datasets of underrepresented populations to enhance the performance of PRSCHD.

The current state and future of cardiometabolic polygenic risk scores in European and non-European population cohorts

Abstract P339: The Clinical Application and Ancestral Diversity of Cardiometabolic Polygenic Risk Scores

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Polygenic risk scores for the prediction of cardiometabolic disease

Polygenic Risk Score Implementation into Clinical Practice for Primary Prevention of Cardiometabolic Disease

Risk assessment for colorectal cancer via polygenic risk score and lifestyle exposure: a large-scale association study of East Asian and European populations

Polygenic risk score portability for common diseases across genetically diverse populations

Methodologies underpinning polygenic risk scores estimation: a comprehensive overview

Polygenic Risk Scores: The Next Step for Improved Risk Stratification in Coronary Artery Disease?

Combining European Society of Cardiology and American College of Cardiology/American Heart Association risk prediction model with polygenic risk scores to refine cardiovascular prevention

Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease Based on an Ancestrally Diverse Genome-Wide Association Study and Population-Specific Optimization

Comparative Performance of Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease Subtypes in the All of Us Research Program

Polygenic risk scores: from research tools to clinical instruments

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Validity of European-centric cardiometabolic polygenic scores in multi-ancestry populations

Clinical use of polygenic risk scores for detection of peripheral artery disease and cardiovascular events

Population Performance and Individual Agreement of Coronary Artery Disease Polygenic Risk Scores

Clinical use of current polygenic risk scores may exacerbate health disparities

Abstract P200: A Polygenic Risk Score Improves Prediction Of Lifetime Risk For Heart Failure

Generalizability of PRS313 for breast cancer risk amongst non-Europeans in a Los Angeles biobank

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models